|
论阿托伐他汀对维持性血液透析患者炎症因子的影响 |
| |
measured before and in 1 and 3 months after treatment.ELISA method was used to measure IL6 and sICAM1 and Radioimmunoassay was used to measure hsCRP.Results: The serum levels of IL6,hsCRP and sICAM1 were significantly decreased in 1 and 3 months after treatment in both groups compare to those before treatment (P<0.05),especially in the 20mg atorvastatin group(P<0.01).The blood pressure was lowered without significant difference in 1 month (P>0.05) but with statistical difference in 3 months in both groups compared to that before treatment (P<0.05) and no difference was noted between the 2 groups.TC,TG and LDLC was reduced in 1 and 3 months (P<0.05) and more reduction of TC and LDLC was found in the 20mg group in 3 months (P<0.05).The serum levels of albumin and HB were significantly increased in both groups(P<0.05).Conclusion:Atorvastatin intervention may improve the microinflammatory state and lipid metabolic disorder in patients during MHD.
Key words uremia hemodialysis atorvastatin inflammatory cytokine
2000年Schoming等[1]提出尿毒症患者存在着“微炎症状态”,这种微炎症是指患者没有全身或局部急性的临床感染征象,但存在低水平持续的炎症状态,表现为炎症因子的轻度升高。目前比较统一的观点认为,原发及各种继发肾脏疾病均存在机体免疫功能异常,自始至终都伴随着炎性因子的异常表达,患者长期血液净化治疗则加重了炎症反应的进展[2]。维持性血液透析(MH上一页 [1] [2] [3] [4] [5] 下一页
上一个医学论文： 浅议黄体剥除预防持续性异位妊娠的临床问题
下一个医学论文： 浅论孟鲁司特合博利康尼防治儿童咳嗽变异性哮喘
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 中医论文 >> 正文